Group 1 - The Hong Kong stock market saw renewed activity in innovative drugs, with companies like Zai Lab, Innovent Biologics, Kelun-Biotech, WuXi Biologics, and InnoCare leading the gains, and the Hang Seng Medical ETF (159892) rising over 2% during the session [1] - Innovent Biologics announced a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, with an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [1] - Donghai Securities highlighted the strong performance of the innovative drug sector, validating the effectiveness of the domestic innovative drug business model, with core products supported by medical insurance driving growth, and external collaborations contributing significantly to performance enhancement [1]
创新药板块强势反弹，恒生医药ETF涨超2%
Mei Ri Jing Ji Xin Wen·2026-02-10 04:44